Loading organizations...
§ Venture Capital · Shanghai
Private investment firm and family office investing in diverse sectors for global investors, focused on real estate, consumer, and technology.
Founded in 2017 by David Teo, Apricot Capital is a private investment firm and family office in Singapore that manages diversified wealth across private equity, venture capital, real estate, and public markets. The firm operates primarily using the private wealth generated from the SGD 1.45 billion sale of the instant food and beverage manufacturer Super Group. Its investment strategy targets diverse asset classes and sectors globally, including consumer lifestyle, education, healthcare, food and beverage, and technology startups. The organization has backed several notable portfolio companies, leading a SGD 5.35 million seed funding round for the co-living startup The Assembly Place and participating in a USD 40 million Series B round for the consumer dental technology brand Zenyum. Other notable venture investments managed by the firm include the robotics and automated coffee startup Crown Digital, expanding its broad portfolio.
Key people at Apricot Capital.
Apricot Capital was founded in 2015 by Peter Wernau (Co-Founder, Managing Partner).
Apricot Capital has 6 tracked investments across 6 companies. The latest tracked deal is $43.4M Series A in Zhiran Medical in February 2026.
| Date | Company | Round | Lead Investor(s) | Co-Investor(s) |
|---|---|---|---|---|
| Feb 11, 2026 | Zhiran Medical | $43.4M Series A | CAS Star, IDG Capital, Legend Capital | Baidu Ventures, Beijing Medical And Health Industry Investment Fund, BioVenture, Jiayin Capital, Lenovo Capital And Incubator Group (LCIG), Longzhu Capital, Sequoia Capital, Shunwei Capital, Beijing Pharmaceutical And Health Industry Investment Fund, China Life Capital, DragonBall Capital |
| Feb 2, 2026 | Microtide Biotechnology | Series A | — | Qiming Venture Partners, Xiamen C&D Corporation |
| Jun 1, 2021 | Float Foods | $2.0M Seed | Insignia Ventures Partners, DSG Consumer Partners | Agrocorp Ventures, Baksh Capital, EBB & Flow, Innovate360, Teja Ventures, Water Tiger Investments |
| Apr 26, 2021 | Hepagene Therapeutics | $40.0M Series B | Loyal Valley Capital | Oceanpine Capital |
| Jun 15, 2020 | Immvira | $58.0M Series B | Huagai Capital | — |
| Aug 5, 2016 | Ambrx | $45.0M Other Equity | Apricot Capital, Northeast Securities | China Everbright, Fosun Pharma, Hopu Investments, Sinopharm Capital |
Key people at Apricot Capital.
Apricot Capital is a leading investment firm founded in 2015 and based in Shanghai, China, with a specialized focus on the healthcare sector, particularly biotech, medtech, and life sciences. Its mission is to nurture groundbreaking innovation and bridge China’s burgeoning biotech ecosystem with the global healthcare landscape. The firm invests primarily in early- and growth-stage companies that address critical unmet clinical needs worldwide, covering areas such as gene therapy, cell therapy, nucleic acid drugs, medical devices, diagnostics, and biotech supporting services like CROs and AI-driven drug discovery. Apricot Capital has built a portfolio with over 70 companies and has transacted more than $12 billion in value, positioning itself as a top 20 healthcare venture capital firm in 2024[1][2].
Apricot Capital was established in 2015 by founding partners Dr. Crystal Liu and Arthur Qiang. The leadership team combines strong academic credentials from prestigious institutions such as Johns Hopkins, Harvard, and Tsinghua University with practical experience in clinical medicine, pharmaceutical analysis, healthcare operations, and entrepreneurship. This blend of scientific insight and financial expertise has shaped the firm’s evolution from a general venture investor to a specialized healthcare-focused firm deeply embedded in China’s life sciences ecosystem. The firm’s growth reflects a strategic focus on incubating and scaling innovative biotech and medtech companies that can compete on a global stage[1].
Apricot Capital rides the global trend of rapid innovation in biotechnology and healthcare, particularly the convergence of advanced therapies (gene and cell therapy), digital health, and AI applications in drug discovery. The timing is critical as China emerges as a major player in life sciences, supported by government initiatives and increasing global collaboration. Apricot Capital’s role is pivotal in bridging Chinese innovation with global markets, accelerating the commercialization of novel therapies and technologies that address significant unmet medical needs. This positions the firm as a key influencer in shaping the future of healthcare innovation both regionally and globally[1].
Looking ahead, Apricot Capital is likely to deepen its investment footprint in transformative biotech and medtech sectors, leveraging its strong scientific and operational expertise to back category-defining companies. Trends such as personalized medicine, AI-driven drug development, and global biotech collaboration will shape its journey. The firm’s influence is expected to grow as it continues to bridge China’s healthcare innovation with international markets, fostering a more integrated global biotech ecosystem. This trajectory aligns with its mission of driving innovation for life and creating lasting impact in healthcare[1].
